HK1251471A1 - 用於治疗肺的癌症的多核苷酸toll样受体9激动剂的肺内施用 - Google Patents

用於治疗肺的癌症的多核苷酸toll样受体9激动剂的肺内施用 Download PDF

Info

Publication number
HK1251471A1
HK1251471A1 HK18110977.6A HK18110977A HK1251471A1 HK 1251471 A1 HK1251471 A1 HK 1251471A1 HK 18110977 A HK18110977 A HK 18110977A HK 1251471 A1 HK1251471 A1 HK 1251471A1
Authority
HK
Hong Kong
Prior art keywords
lung
receptor
agonists
intrapulmonary administration
treating cancer
Prior art date
Application number
HK18110977.6A
Other languages
English (en)
Chinese (zh)
Inventor
Cristiana Guiducci
Robert L. Coffman
Original Assignee
Dynavax Technologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Technologies Corporation filed Critical Dynavax Technologies Corporation
Publication of HK1251471A1 publication Critical patent/HK1251471A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18110977.6A 2015-05-29 2016-05-23 用於治疗肺的癌症的多核苷酸toll样受体9激动剂的肺内施用 HK1251471A1 (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US201562168470P 2015-05-29 2015-05-29
US62/168,470 2015-05-29
US62/168,449 2015-05-29
US201562169321P 2015-06-01 2015-06-01
US201562169309P 2015-06-01 2015-06-01
US62/169,321 2015-06-01
US62/169,309 2015-06-01
US201662276767P 2016-01-08 2016-01-08
US62/276,767 2016-01-08

Publications (1)

Publication Number Publication Date
HK1251471A1 true HK1251471A1 (zh) 2019-02-01

Family

ID=56098419

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110977.6A HK1251471A1 (zh) 2015-05-29 2016-05-23 用於治疗肺的癌症的多核苷酸toll样受体9激动剂的肺内施用

Country Status (14)

Country Link
US (3) US9993495B2 (cg-RX-API-DMAC7.html)
EP (2) EP3302502B1 (cg-RX-API-DMAC7.html)
JP (1) JP6792294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102779525B1 (cg-RX-API-DMAC7.html)
CN (1) CN107708706A (cg-RX-API-DMAC7.html)
AU (1) AU2016270782B2 (cg-RX-API-DMAC7.html)
CA (1) CA2987237A1 (cg-RX-API-DMAC7.html)
DK (1) DK3302502T3 (cg-RX-API-DMAC7.html)
ES (2) ES2752063T3 (cg-RX-API-DMAC7.html)
HK (1) HK1251471A1 (cg-RX-API-DMAC7.html)
IL (1) IL255903B (cg-RX-API-DMAC7.html)
MX (1) MX381587B (cg-RX-API-DMAC7.html)
RU (1) RU2017145940A (cg-RX-API-DMAC7.html)
WO (1) WO2016196062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CA2964155A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
JP2022505318A (ja) * 2018-10-18 2022-01-14 ドイチェス クレブスフォルシュンクスツェントルム 吸入用乾燥医薬組成物
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
WO2020128893A1 (en) * 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US11613755B2 (en) * 2019-12-31 2023-03-28 Industrial Technology Research Institute Nucleic acid-drug complex and use thereof
US12686870B2 (en) 2020-01-10 2026-07-21 Sbi Biotech Co., Ltd. TLR9 agonists
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
CN114099535B (zh) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物
EP4267136A4 (en) * 2020-12-23 2025-02-05 Cascade Prodrug Inc. Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
US20250009731A1 (en) 2021-11-08 2025-01-09 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
AU2023209887A1 (en) * 2022-01-21 2024-08-15 Trisalus Life Sciences, Inc. Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
DE60334303D1 (de) * 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DK1992635T3 (da) * 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
CN101134046B (zh) * 2006-09-01 2011-10-05 中国医学科学院药物研究所 Tlr4和tlr9激动剂复方在抑制肿瘤转移中的应用
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Tlr9の合成アゴニスト
CA2836676A1 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
MX2017015311A (es) * 2015-05-29 2018-06-19 Merck Sharp & Dohme Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
CA3020873A1 (en) * 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer

Also Published As

Publication number Publication date
US20190151345A1 (en) 2019-05-23
US9993495B2 (en) 2018-06-12
CN107708706A (zh) 2018-02-16
WO2016196062A1 (en) 2016-12-08
RU2017145940A3 (cg-RX-API-DMAC7.html) 2019-11-26
EP3590518B1 (en) 2024-03-20
DK3302502T3 (da) 2019-10-28
EP3302502A1 (en) 2018-04-11
KR102779525B1 (ko) 2025-03-12
KR20180021700A (ko) 2018-03-05
AU2016270782B2 (en) 2021-08-12
US10369168B2 (en) 2019-08-06
CA2987237A1 (en) 2016-12-08
NZ737488A (en) 2024-12-20
MX381587B (es) 2025-03-12
AU2016270782A1 (en) 2017-12-07
US20160346312A1 (en) 2016-12-01
ES2752063T3 (es) 2020-04-02
IL255903B (en) 2021-09-30
US20180264023A1 (en) 2018-09-20
ES2987696T3 (es) 2024-11-15
RU2017145940A (ru) 2019-07-02
EP3590518A1 (en) 2020-01-08
JP2018521011A (ja) 2018-08-02
JP6792294B2 (ja) 2020-11-25
IL255903A (en) 2018-01-31
MX2017015294A (es) 2018-02-19
US10111899B2 (en) 2018-10-30
EP3302502B1 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
MX381587B (es) Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos.
IL243788B (en) New immunotherapy against various tumors such as lung cancer which includes nsclc
IL295031B1 (en) Innovative immunotherapy against several tumors, such as lung cancer, including nsclc
DK3140319T3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
EP3443119B8 (en) Methods for lung cancer detection
GB2572610B (en) Composition, methods for its production, and its use
PH12016501763B1 (en) Multispecific antibodies
SG10201803042PA (en) Anti-tim-3 antibodies
GB201411037D0 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
SG10201601501QA (en) Preparation of 2,2`-biaryls in the presence of molybdenum(v) chloride
SG10201507607RA (en) Process For Producing Traditional Chinese Medicine Compositions, And Compositions Obtainable By The Process
EP3298182A4 (en) Methods and compositions for diagnosing or detecting lung cancers
EP3325608A4 (en) METHODS AND MICROORGANISMS FOR PRODUCING 1,3-BUTANEDIOL
EP3124574A4 (en) Coal mixture, method for producing coal mixture, and method for producing coke
WO2015179835A3 (en) Mit biomarkers and methods using the same
EP3283654A4 (en) Methods for typing of lung cancer
IL248203A0 (en) Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord
MX395174B (es) Composiciones de triptamina y metodos de uso.
EP3156502A4 (en) Evaluation method for evaluating the likelihood of breast cancer
GB201403297D0 (en) Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
GB201313987D0 (en) Novel immunotherapy against several tumors, such as lung cancer including NSCLC
岡壮一 Epidermal growth factor receptor-GEP100-Arf6 axis affects the prognosis of lung adenocarcinoma.(EGFR-GEP100-Arf6
GB201611533D0 (en) 2-O, 3-O-desulfated heparin derivatives with reduced content of reactive saccharides
HK1260066A1 (en) Methods for lung cancer detection
SG11201608794TA (en) 2,3,3,3-tetrafluoro-1-propene as diluent for the preparation of novel butyl rubbers